ATR
XNYS
Market cap8.88bUSD
Nov 20, Last price
140.08USD
1D
-0.19%
1Q
3.92%
Jan 2017
90.71%
Name
Aptargroup Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
Related entities
Subsidiaries (24)
Aptar Czech Republic s.r.o.
Aptar Dortmund GmbH
APTAR EL MARQUES, S. de R.L. de C.V.
Aptar Europe Holding SAS
APTAR FRANCE SAS
Aptar Freyung GmbH
Aptar Global Business Services CZ s.r.o.
APTAR ITALIA S.P.A.
Aptar Mezzovico Sa
Aptar Pharma India Private Limited
Aptar Pharma Services, Inc.
APTAR QUERETARO S DE RL DE CV
Aptar Radolfzell GmbH
APTAR STELMI SAS
APTAR UK LIMITED
Aptar Villingen GmbH
AptarGroup International Holding S.a r.l.
APTARGROUP INTERNATIONAL INVESTMENT LIMITED
APTARGROUP UK HOLDINGS LIMITED
brisath xaephtar (prathesthiy) cakad
Key people
President, Chief Executive Officer, Director · since 2017
Marc Prieur
President - Aptar Beauty · since 2023
Hedi Tlili
President - Aptar Closures · since 2023
Gael Touya
President - Aptar Pharma · since 2018
Shiela Vinczeller
Chief Human Resources Officer · since 2018
Executive Vice President, Chief Legal Officer and Corporate Secretary · since 2021
Xiangwei Gong
Executive Vice President - Strategic Group Development and President, Aptar Asia · since 2025
Vanessa Kanu
Chief Financial Officer, Executive Vice President · since 2025
Independent Director · since 2023
Independent Director · since 2023
Giovanna Kampouri Monnas
Independent Director · since 2010
Isabel Marey-Semper
Independent Director · since 2019
Independent Chairman of the Board · since 2023
B. Craig Owens
Independent Director · since 2018
Matthew Trerotola
Independent Director · since 2022
Ralf Wunderlich
Independent Director · since 2009
Julie Xing
Independent Director · since 2023
Legal address
c/o COGENCY GLOBAL INC., 850 New Burton Road Suite 201
Dover, DE 19904
US
Dover, DE 19904
US
Headquarters
265 Exchange Drive
Crystal Lake, IL 60014
US
Crystal Lake, IL 60014
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||